VRDN (45) NRIX (42) MBX (44) IDYA (45) ⌘ Pro Terminal →

Vicore Pharma Holding AB (VCRE) — RQD Stock Rating Cockpit

$10.20 +4.56% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $10.26

Vicore Pharma Holding AB (VCRE) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY) →

ROARABLE C- • HOLD / WATCH Cap $2.87B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $10.26 (+0.63%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 2% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record: Scores of 61/100 (C-) historically posted market-perform odds over rolling 90-day windows (+0.5% avg 90D alpha vs SPY • 53.9% hit rate — wait for RQD ≥ 70 breakout).

Audit Bucket Track Record →

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1.4% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for VCRE)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (61/100 Composite)

🔍 WHY VCRE SCORES 61/100 (C-) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (25% of score)

FRED Regime × Technicals: 23% of 52W Range • RSI-14 at 51.9 (NEUTRAL RANGE)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (21% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution9/20 pts (-11 pt drag)

Disciplined Float (-0.40% YoY Shares) & executive Form 4 sales trim 11 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$9.00-0.2% Next Q

Q2 (-2Q)

Grade C$8.98+4.5% Next Q

Q3 (-1Q)

Grade C$9.38+8.7% Next Q

Current

Grade C-$10.20+0.5% Hist 90D α

Trajectory: C- (53) → C- (61)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the VCRE Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 61/100 (C-) score, VCRE faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Company executives have done more routine share selling than personal cash buying lately.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Disciplined Float (-0.40% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($10.15) or 200D SMA ($11.00) invalidates the momentum regime and cuts Target Base ($10.34) toward Bear Floor ($8.07).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $VCRE• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “VCRE Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”

YES 61%NO 39%Trade / Inspect Odds →

RSI-14 MOMENTUMNEUTRAL RANGE

51.930 Oversold · 70 Hot

ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)

3.80>3.0 Fortress Safe

PIOTROSKI F-SCOREHIGH QUALITY (7–9)

7 / 99-Pt Accounting

52-WEEK LASER RANGE23% OF RANGE

L: $8$10.20H: $18

1. Money & Cash Health● MIXED

Are profits real cash in the bank?

Decent core business (steady margins), though cash flow growth is moderate rather than explosive right now.

Factor Grade: C-RQD 12 / 20

2. Big Money & Insiders● TRIMMING

Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: D+RQD 21 / 40

3. Hidden Risks & Market Weather● ALL CLEAR

SEC fine-print scan & interest-rate fit

Clean SEC fine-print check with low hidden accounting risk and favorable interest-rate weather.

Factor Grade: B-RQD 28 / 40

MULTI-MODEL JEV QUANT JURY DELIBERATION

JEV AI Jury Split (Battleground) on VCRE

Cash & Moat Bull AI

ROIC & Free Cash Flow Model

NEUTRAL (60)

14.0% ROIC with 42.0% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI

10-K Accruals & Altman-Z Guard

NEUTRAL (65)

Altman-Z 4.20 and Piotroski 7/9 pass balance-sheet audit.

Whale & Macro Hawk AI

Options Skew, 13F & Fed NetLiq

NEUTRAL (60)

21/40 institutional & smart-money positioning score with 15/20 macro alignment.

Bull Case: Why Buyers Like VCRE

✓Established market leader in Health Care with deep daily trading liquidity.

Bear Case: What Could Go Wrong

!Company executives have done more routine share selling than personal cash buying lately.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (VCRE Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

VCRE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -37.23%▼ DESCENDING CHANNEL

2026-10-30O $10.03H $10.20L $9.70C $10.20VOL 11.9K

RES: $11.22SUP: $6.12SMA50: $10.15SMA200: $11.00

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

VCRE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 VCRE Butterfly Map → + Track VCRE →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on VCRE today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for VCRE. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for VCRE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (VCRE)

Health Care Rank #181 of 1016 ⚔️ VRDN vs VCRE Full Matrix →

1. Head-to-Head Health Care Peer Comparison (VCRE vs. VRDN, NRIX, MBX, IDYA)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Vicore Pharma Holding AB (VCRE) ranks #181 by composite RQD confidence (61/100, grade C-) and #212 by equity capitalization ($2.87B). Within this direct 5-issuer industry benchmark cohort, VCRE leads on earnings valuation at N/A trailing P/E, while IDYA leads on capital efficiency and profitability with -13.8% ROIC and — gross margin. VCRE currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
VCRE ACTIVE Vicore Pharma Holding AB	C-	61/100	—	—	—	+4.56%	$2.87B	Benchmark Subject
VRDN Viridian Therapeutics Inc.	D	45/100	—	—	-35.0%	+2.18%	$2.81B	/vrdn-vs-vcre →
NRIX Nurix Therapeutics Inc.	D-	42/100	—	—	-35.0%	-0.51%	$2.96B	/nrix-vs-vcre →
MBX MBX Biosciences Inc.	D	44/100	—	—	-26.4%	+0.70%	$2.63B	/mbx-vs-vcre →
IDYA IDEAYA Biosciences Inc.	D	45/100	—	—	-13.8%	-3.15%	$3.17B	/idya-vs-vcre →

2. VCRE Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

Vicore Pharma Holding AB (VCRE) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $2.87B, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. VCRE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is VCRE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Vicore Pharma Holding AB (NASDAQ: VCRE) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $10.20 (+4.56% 1D, market cap $2.87B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, VCRE ranks #181 in composite RQD confidence.

How does VCRE compare to VRDN and NRIX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), VCRE carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, VRDN (Viridian Therapeutics Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $2.81B) and NRIX (Nurix Therapeutics Inc.) posts a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $2.96B). Among the 5-stock peer group, VCRE leads on earnings multiple (N/A) while IDYA leads on capital efficiency (-13.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for VCRE?

For Vicore Pharma Holding AB (VCRE), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity. and sector rank #181 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately. and implied 5-year growth hurdle of 8.0%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is VCRE trading relative to its 50-day, 200-day, and 52-week technical levels?

VCRE last traded at $10.20 (+4.56% on volume of 37,008 shares), positioning the stock +0.49% above its 50-day simple moving average ($10.15) and -7.27% below its 200-day simple moving average ($11.00). Across its 52-week range of $7.88 to $17.80, VCRE sits at the 23.4% percentile with a 14-day RSI of 51.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($8.93 to $11.47).

VCRE Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Should I buy, hold, or sell VCRE stock right now?

Vicore Pharma Holding AB (VCRE) currently earns a Roarable Rating of C- (Hold — HOLD) with 61/100 RQD Confidence. Solid steady margins (steady margins), mixed timing at current multiples—hold if owned, no rush to chase.

What is VCRE's 12-month price target and RQD AI Jury consensus?

VCRE's 12-month base price target is $10.34 (range $8.07 to $18.69), backed by transparent SEC XBRL cash-flow, Form 4 insider, and CBOE options flow analysis.

Direct Sub-Reports: VCRE RQD Cockpit VCRE 12M Forecast VCRE Earnings & Move VCRE Dividends & DRIP VCRE Insiders & 13F VCRE Whale Options VCRE Profit Sankey VCRE News & Why